The drug comes with a hefty price of $580 for a 60g ... but is now also in development for eczema. Sanofi and Regeneron have an injectable drug Dupixent (dupilumab), but this is more acute ...

The study met its primary endpoint, but analysts compared the results unfavorably to the data on Dupixent. Adjusted for placebo, 19.1% of people on rocatinlimab had 75% improvement in eczema area ...

OBJECTIVE To evaluate the impact of childhood atopic eczema on families and assess the personal financial cost of its management. DESIGN Cross sectional survey. SETTING Paediatric dermatology and ...

eczema, and other conditions. Blocking IL-4 and IL-13 from working can decrease the swelling that causes these conditions. Dupixent should be kept in its original carton to protect it from light.

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab ... Monthly in-depth briefings on Boardroom appointments and M&A news. Choose from a cost-effective annual package ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab ... Choose from a cost-effective annual package ...

overall rates of adverse events (AEs) were 96% (n=51) for Dupixent and 96% (n=51) for placebo. AEs more commonly observed with Dupixent compared to placebo in at least 3 patients included peripheral ...